What happened with MDXG today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
MiMedx Group, Inc supplies products that clinicians use to treat chronic, hard-to-heal wounds and to close wounds or protect and reinforce tissue during surgery. Wound care generates most of its revenue, with surgery providing a substantial second business; sales are overwhelmingly in the United States. Its portfolio includes EPIFIX and EPICORD for wound care and AMNIOFIX for surgery.
The company obtains donated human birth tissue through hospitals and other donation providers, then processes placental tissue into grafts using its proprietary PURION method. It also sells animal-derived and other products made by outside suppliers. Hospitals, wound-care clinics and physician offices buy its products through its sales team and independent agents; distributors buy products wholesale for resale.
Most healthcare customers rely on insurers or government health programs to reimburse treatment, so sales depend on clinicians choosing the products and payers covering their use. Medicare now uses a standardized payment rate for skin substitutes across hospital outpatient and physician-office settings. FDA rules also limit how products may be marketed and used. AXIOFILL remains on sale while MiMedx challenges the FDA’s determination that it needs more extensive regulation, but the legal outcome could end those sales.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
MIMEDX’s results hinge on skin-substitute reimbursement and clinician adoption, making Organogenesis a key direct rival to watch even though it is absent from this list.
Celularity competes with MIMEDX by selling placenta-derived materials for wound care, soft-tissue repair and reconstruction, directly or through distributors. Watch sales of Biovance 3L and Rebound, the main products in its biomaterials business, for signs of competition for these treatments.
Integra LifeSciences competes with MIMEDX in products that cover wounds and repair tissue, but its larger neurosurgery business makes overall results a less direct comparison. Watch its Tissue Technologies revenue rather than total revenue for the closer read on competition in skin substitutes and tissue repair.
Smith & Nephew competes with MIMEDX to sell skin substitutes to wound-care providers, but its much broader medical-technology business makes group revenue a less direct guide. Watch reimbursement and clinician uptake of its skin substitutes, where providers weigh coverage alongside efficacy and ease of handling.
SANUWAVE sells providers an ultrasound treatment for chronic wounds, competing for treatment choices that also include MIMEDX grafts. Watch UltraMIST consumable sales for a view of spending on this non-contact treatment, which sends ultrasound through a fluid mist to the wound.
Solventum sells advanced dressings, systems that apply suction to wounds and synthetic tissue matrices to providers who also buy MIMEDX grafts. Its wound-care product sales are the relevant comparison; MedSurg revenue also includes many other medical and surgical supplies.
AVITA Medical’s skin-restoration products and matrices overlap with the burn and surgical tissue-repair products MIMEDX sells to healthcare providers. Watch uptake of RECELL, PermeaDerm and Cohealyx in acute wound care for competition facing MIMEDX’s Surgical business, rather than its chronic-wound portfolio.
Integra LifeSciences Holdings earningsIART
Integra LifeSciences' Tissue Technologies business will show whether competition remains strong in skin substitutes and tissue repair, where it overlaps with MiMedx's Wound business.
Watch Tissue Technologies sales, not Integra's total revenue. Stronger sales would show that competition in these products remains active, keeping pressure on MiMedx's Wound business. Weaker sales could mean less competitive pressure, but would not show that customers switched to MiMedx.
MiMedx Group, Inc earningsThis company
MiMedx's report will show whether its Wound sales can keep growing and its gross margin hold up under the new reimbursement rules for skin substitutes.
Compare Wound sales with Surgical sales, then read both alongside companywide gross margin. If Wound sales keep growing and margin holds, product mix and sales are offsetting some reimbursement pressure. If Wound sales weaken and margin falls, reimbursement changes and related costs are outweighing those buffers.
Avita Medical, Inc. earningsRCEL
Avita Medical's acute-wound product sales will show whether providers are using more of the treatments that overlap with MiMedx's Surgical business.
Watch sales or uptake of RECELL, PermeaDerm and Cohealyx, focusing on acute wound care. Greater uptake would show these treatments competing for the procedures and burn cases that MiMedx's Surgical products serve. Weaker uptake would offer less evidence of that pressure, but would not mean MiMedx won those cases.
Solventum Corporation earningsSOLV
Solventum's wound-care product sales will show whether overall buying is strengthening or weakening among providers that also purchase MiMedx grafts.
Watch Solventum's wound-care product sales, not total MedSurg revenue. Stronger sales would show that shared providers are still buying wound-care products; weaker sales could point to slower purchasing. Solventum sells a broad range of products, so its results cannot establish that demand for MiMedx grafts moved by the same amount.
